New drug targets KRAS-Mutated cancers in early trial
NCT ID NCT06973564
First seen Nov 12, 2025 · Last updated Apr 30, 2026 · Updated 19 times
Summary
This study tests a new drug called JAB-23E73 in adults with advanced solid tumors that have a specific genetic change (KRAS alteration). The main goals are to find safe doses and check for early signs that the drug can shrink tumors. About 294 participants will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Foundation
RECRUITINGCleveland, Ohio, 44195, United States
-
Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.